On September 11, 2009, Berger, Dan Maarten; Levin, Jeremy Ian; Dutia, Minu Dhanjisha; Norton, Emily Boucher; Diamantidis, George published a patent.Application of 40644-16-4 The title of the patent was Preparation of aminosulfonylphenyl pyrazolo[1,5-a]pyrimidines as Raf kinase inhibitors.. And the patent contained the following:
Title compounds [I; R = H, halo, NO2, N3, cyano, CHO, CF3, OCF3, R5, OR5, N(R5)2, etc.; R1 = (substituted) heteroaryl, heterocyclyl; R2 = (substituted) aryl, heteroaryl, heterocyclyl; R3, R4 = H, (substituted) alkyl, cycloalkyl, heteroaryl; R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl; N(R5)2 = atoms to form a substituted ring containing 2-7 C atoms], were prepared Thus, N-[2-(diethylamino)ethyl]-N-ethyl-3-[3-(3-hydroxyphenyl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]benzenesulfonamide (multistep preparation given) inhibited B-Raf kinase with IC50 <0.0003 μM. The experimental process involved the reaction of 4-Bromo-1H-benzo[d]imidazol-2(3H)-one(cas: 40644-16-4).Application of 40644-16-4
The Article related to phenylsulfonamide pyrazolopyrimidine preparation raf kinase inhibitor, cancer inflammation treatment aminosulfonylphenylpyrazolopyrimidine preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Application of 40644-16-4
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem